Nuvation Bio announced today that its leadership will take part in two upcoming investor conferences. The company’s founder and CEO, David Hung, M.D., along with CFO Philippe Sauvage, will join fireside chats. First, they will speak at the 8th Annual Evercore Healthcare Conference on December 2, 2025 in Miami. Then, they will appear at the Citi 2025 Global Healthcare Conference on December 3, 2025.
The company said that live webcasts of both sessions will stream on its Investor Relations website. Additionally, on-demand recordings will remain accessible for 90 days after each event.
Nuvation Bio works globally in oncology. It develops advanced cancer therapies, including next-generation inhibitors and other targeted treatments. Thus, the firm uses these conferences to showcase its drug pipeline and strategic vision.
Furthermore, participation allows analysts and investors to engage directly with company leadership. They can ask detailed questions about drug development, regulatory plans, and commercial strategy. Moreover, the events offer a platform to reaffirm confidence in Nuvation Bio’s long-term growth and innovation potential.
Overall, Nuvation Bio’s conference appearances underline its commitment to transparency and investor communication. As the company advances its oncology pipeline, management aims to strengthen stakeholder trust while highlighting its mission to address tough cancer challenges globally.
Looking for more updates on financial innovation and revenue-driven technology? Visit RevTech News for expert insights and the latest trends.
News Source: Businesswire.com
